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Patients and Methods:
We retrospectively reviewed medical records of 51 MDR-TB patients, including 26 patients (51%)
with XDR-TB to evaluate the safety, tolerability and efficacy of daily 300 mg dose of linezolid therapy. All patients had failed to previous treatment with second-line anti-TB drugs.
Results: The patients were treated with linezolid for a median period of 413 days [interquartile range (IQR) 237-622 days].
Negative sputum conversion was achieved in 40 (78%) patients after a median of 55 days (IQR 41-91 days) from the start of linezolid therapy. Eleven (22%) patients had unsuccessful outcomes. Fourteen (27%) patients discontinued linezolid due to neurotoxicity such as peripheral and optic neuropathy after a median of 278 days (IQR 174-412 days).
Conclusions: A daily 300 mg dose of linezolid may be useful in the treatment of MDR and XDR-TB. However, peripheral and optic neuropathy is a major problem associated with the long-term use of linezolid.
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